FBCE yields 2000000.00% · ABBV yields 3.06%● Live data
📍 FBCE pulled ahead of the other in Year 1
Combined, FBCE + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FBCE + ABBV for your $10,000?
FiberCore, Inc. develops, manufactures, and markets single-mode and multimode optical fiber, and optical fiber preforms for the telecommunications and data communications industry. The company's principal operating units are FiberCore Jena A.G. (FCJ), its wholly owned subsidiary in Germany; and Xtal FiberCore Brasil S.A. (Xtal), the company's 90% owned subsidiary in Campinas, Brazil. FCJ manufactures both multimode and single-mode fiber and preforms with an emphasis on the multimode market; Xtal manufactures both single-mode and multimode fiber, and single-mode preforms with an emphasis on the single-mode market. Through its subsidiary, FiberCore Systems, Inc., the company designs, installs, and maintains optical fiber networks, wide area networks, and non-fiber optic networks primarily in the Northeast U.S., for local area network applications, such as those used in hospitals, universities, government, and commercial buildings. The company markets its optical fiber products under the trademarks, InfoGlas®, EconoGrade®, and ValuGrade®. Fibercore competes with Corning, Inc.; Furukawa/OFS; Alcatel; Draka; Samsung; and Sumitomo. FiberCore, Inc. was founded in 1987 and is based in Charlton, Massachusetts. On October 6, 2004 the voluntary petition of FiberCore, Inc. for reorganization under Chapter 11 was converted to liquidation under Chapter 7. The Company had filed for Chapter 11 on November 14, 2003.
Full FBCE Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.